biostudies-literatureUnknown31(2)Di Costanzo F<h4>Context</h4>With new treatment strategies approved in metastatic hormone-sensitive prostate cancer (mHSPC), heterogeneity across trials hinders the physicians' choice for first-line treatment.<h4>Objective</h4>We conducted a systematic review and network meta-analysis to assess the efficacy of currently approved treatments for mHSPC stratifying patients according to their disease burden (high- vs. low-volume as per CHAARTED criteria) and onset of metastatic disease (synchronous vs. metachronous).<h4>Intervention</h4>Eleven randomized controlled trials (RCTs) published until October 30, 2024 were included. Treatment regimens were grouped as triplets for combinations of docetaxel, androgen receptor pathway inhibitors (ARPIs) and androgen-deprivation therapy (ADT), separate doublets for dThe oncologistoyaf386https://www.ebi.ac.uk/biostudies/studies/S-EPMC12832964biostudies-literatureBest therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis.PMC12832964Briganti AConteduca VDima GRebuzzi SEMaiorano BAMercinelli CFornarini GFormisano LRescigno PSantoni MDe Giorgi UCaffo OMessina CSignori AProcopio GBanna GLMontorsi FDi Costanzo FOing CNecchi AGalli LDi Maio MfalseBest therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis.<h4>Context</h4>With new treatment strategies approved in metastatic hormone-sensitive prostate cancer (mHSPC), heterogeneity across trials hinders the physicians' choice for first-line treatment.<h4>Objective</h4>We conducted a systematic review and network meta-analysis to assess the efficacy of currently approved treatments for mHSPC stratifying patients according to their disease burden (high- vs. low-volume as per CHAARTED criteria) and onset of metastatic disease (synchronous vs. metachronous).<h4>Intervention</h4>Eleven randomized controlled trials (RCTs) published until October 30, 2024 were included. Treatment regimens were grouped as triplets for combinations of docetaxel, androgen receptor pathway inhibitors (ARPIs) and androgen-deprivation therapy (ADT), separate doublets for d2026-01-01T00:00:00Z2026 Jan2026-06-06T03:22:06.754Z2026-06-06T03:10:44.804ZS-EPMC128329644124710110.1093/oncolo/oyaf386